
Eva M Putz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7176547/publications.pdf Version: 2024-02-01



Ενλ Μ Ρυτζ

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. Oral Oncology, 2022, 124, 105634. | 1.5 | 9 |
| 2 | Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nature Communications, 2020, 11, 4166. | 12.8 | 53 |
| 3 | Loss of NKG2D in murine NK cells leads to increased perforin production upon longâ€ŧerm stimulation with ILâ€2. European Journal of Immunology, 2020, 50, 880-890. | 2.9 | 9 |
| 4 | JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. Frontiers in Immunology, 2019, 10, 2590. | 4.8 | 110 |
| 5 | Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 2018, 33, 634-648.e5. | 16.8 | 163 |
| 6 | NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses. Cancer Immunology Research, 2018, 6, 458-466. | 3.4 | 40 |
| 7 | Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 2018, 132, 694-706. | 1.4 | 132 |
| 8 | Bench to bedside: NK cells and control of metastasis. Clinical Immunology, 2017, 177, 50-59. | 3.2 | 71 |
| 9 | Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncolmmunology, 2017, 6, e1267892. | 4.6 | 53 |
| 10 | Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis. Cancer Immunology Research, 2017, 5, 1098-1108. | 3.4 | 98 |
| 11 | NK cell heparanase controls tumor invasion and immune surveillance. Journal of Clinical Investigation, 2017, 127, 2777-2788. | 8.2 | 85 |
| 12 | CIS is a potent checkpoint in NK cell–mediated tumor immunity. Nature Immunology, 2016, 17, 816-824. | 14.5 | 289 |
| 13 | Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncolmmunology, 2016, 5, e1186314. | 4.6 | 13 |
| 14 | Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nature Communications, 2016, 7, 12528. | 12.8 | 25 |
| 15 | STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discovery, 2016, 6, 414-429. | 9.4 | 124 |
| 16 | Abstract IA27: Novel natural killer cell targets for cancer immunotherapy. , 2016, , . | | 0 |
| 17 | ID: 77. Cytokine, 2015, 76, 79. | 3.2 | 0 |
| 18 | Myeloid <i>STAT3</i> promotes formation of colitis-associated colorectal cancer in mice. OncoImmunology, 2015, 4, e998529. | 4.6 | 24 |

ΕνΑ Μ ΡυτΖ

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | In vivotumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncolmmunology, 2015, 4, e1047579. | 4.6 | 27 |
| 20 | Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers, 2014, 6, 193-210. | 3.7 | 13 |
| 21 | STAT1-S727 - the license to kill. Oncolmmunology, 2014, 3, e955441. | 4.6 | 9 |
| 22 | PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia, 2014, 28, 629-641. | 7.2 | 56 |
| 23 | NK cell development in bone marrow and liver: site matters. Genes and Immunity, 2014, 15, 584-587. | 4.1 | 15 |
| 24 | CD52 is a molecular target in advanced systemic mastocytosis. FASEB Journal, 2014, 28, 3540-3551. | 0.5 | 24 |
| 25 | Loss of STAT3 in murine NK cells enhances NK cell–dependent tumor surveillance. Blood, 2014, 124, 2370-2379. | 1.4 | 90 |
| 26 | CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. Cell Reports, 2013, 4, 437-444. | 6.4 | 104 |
| 27 | Targeting PI3Kl´. Oncolmmunology, 2013, 2, e22272. | 4.6 | 0 |
| 28 | The Tyrosine Kinase Btk Regulates the Macrophage Response to Listeria monocytogenes Infection. PLoS ONE, 2013, 8, e60476. | 2.5 | 18 |
| 29 | CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Intrinsic Activity, 2013, 1, A3.4. | 0.0 | 0 |
| 30 | Bcl-2. Oncolmmunology, 2012, 1, 749-750. | 4.6 | 2 |
| 31 | Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncolmmunology, 2012, 1, 1027-1037. | 4.6 | 53 |
| 32 | STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. , 2012, , 187-204. | | 0 |
| 33 | PI3KδIs Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes. PLoS ONE, 2012, 7, e40852. | 2.5 | 30 |
| 34 | PS2-084 Dissection of kinase-dependent and -independent functions of Tyk2 in immunity to infection and tumor-surveillance. Cytokine, 2011, 56, 86. | 3.2 | 0 |
| 35 | The cooperating mutation or "second hit―determines the immunologic visibility toward MYC-induced murine lymphomas. Blood, 2011, 118, 4635-4645. | 1.4 | 30 |
| 36 | PI3Kl̃´is indispensable for CTL-mediated cytotoxicity. BMC Pharmacology, 2011, 11, . | 0.4 | 0 |

ΕνΑ Μ ΡυτΖ

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | In Vivo Long-Term Kinetics of Radiolabeled N,N-Dimethyltryptamine and Tryptamine. Journal of Nuclear Medicine, 2011, 52, 970-977. | 5.0 | 32 |
| 38 | Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. Cancer Research, 2009, 69, 203-211. | 0.9 | 29 |
| 39 | Unexpected role of STAT1 serine727 for NK cell function. BMC Pharmacology, 2009, 9, . | 0.4 | Ο |
| 40 | STAT1 Ser727 – key regulator for NK cell-mediated cytotoxicity and tumor surveillance. BMC Pharmacology, 2008, 8, . | 0.4 | 0 |
| 41 | Leukemic challenge unmasks a requirement for PI3Kδ in NK cell–mediated tumor surveillance. Blood, 2008, 112, 4655-4664. | 1.4 | 48 |